Literature DB >> 28431776

Gliclazide.

Fatmah A M Al-Omary1.   

Abstract

Gliclazide is a second-generation oral hypoglycemic drug used for the treatment of noninsulin-dependent diabetes mellitus. It belongs to the sulfonylurea class that stimulates insulin secretion from pancreatic β-cells by inhibiting ATP-dependent potassium channels. Gliclazide also possesses unique antioxidant properties and other beneficial hemobiological effects. This profile represents a comprehensive description of the physical properties, chemical synthesis, spectroscopic characterization (FTIR, 1H NMR, 13C NMR, UV, and single-crystal X-ray), methods of analysis, pharmacological actions, and pharmacokinetic and pharmacodynamic properties of the title drug.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antioxidant activity; Chemical synthesis; Diabetes mellitus; Gliclazide; Hypoglycemic agent; Pharmacokinetics; Single-crystal X-ray diffraction; Spectroscopy; Toxicity

Mesh:

Substances:

Year:  2017        PMID: 28431776     DOI: 10.1016/bs.podrm.2017.02.003

Source DB:  PubMed          Journal:  Profiles Drug Subst Excip Relat Methodol        ISSN: 1871-5125


  2 in total

1.  Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis.

Authors:  Weiheng Wen; Jinru Gong; Peili Wu; Min Zhao; Ming Wang; Hong Chen; Jia Sun
Journal:  FEBS Open Bio       Date:  2019-02-06       Impact factor: 2.693

Review 2.  Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales.

Authors:  Amelia D Dahlén; Giovanna Dashi; Ivan Maslov; Misty M Attwood; Jörgen Jonsson; Vladimir Trukhan; Helgi B Schiöth
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.